Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)
| 0.6711 Delayed Data As of Jun 02 |  +0.0168 / +2.57%Today’s Change | 0.50 Today|||52-Week Range 2.41 | +0.61% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $8.4M |
Company Description
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Contact Information
Cyclacel Pharmaceuticals, Inc. 200 Connell Drive Berkeley Heights New Jersey 07922 |
Employees
Shareholders
| Other institutional | 23.53% |
| Individual stakeholders | 2.11% |
| Mutual fund holders | 1.69% |
Top Executives
| Spiro Rombotis | President, Chief Executive Officer & Director |
| Paul McBarron | Secretary, Chief Operating & Financial Officer |
| Mark Kirschbaum | Chief Medical Officer & Senior Vice President |
